Tourmaline Bio Announces Board and Executive Changes
| Field | Detail |
|---|---|
| Company | Tourmaline Bio, Inc. |
| Form Type | 8-K |
| Filed Date | Sep 12, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
Tourmaline Bio shakes up board & exec pay effective Sept 8.
AI Summary
Tourmaline Bio, Inc. announced on September 8, 2025, changes in its board and executive compensation. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for its key executives. These changes are effective as of September 8, 2025.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, potentially impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate internal shifts that may affect future performance or strategy.
Key Numbers
- 001-40384 — SEC File Number (Company's SEC filing identifier)
- 83-2377352 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Tourmaline Bio, Inc. (company) — Registrant
- September 8, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 27 West 24th Street, Suite 702, New York, NY 10010 (address) — Principal Executive Offices
- Talaris Therapeutics, Inc. (company) — Former Company Name
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates the departure of certain officers and directors but does not specify the exact roles in this summary.
Who are the newly elected directors?
The filing mentions the election of directors but does not name them in the provided text.
What are the details of the compensatory arrangements for certain officers?
The filing notes adjustments to compensatory arrangements but does not provide specific details on the nature or value of these arrangements.
What is the effective date of these changes?
The changes reported in this 8-K filing are effective as of September 8, 2025.
Has Tourmaline Bio, Inc. undergone a name change previously?
Yes, the company was formerly known as Talaris Therapeutics, Inc., with a date of name change on October 7, 2020.
Filing Stats: 805 words · 3 min read · ~3 pages · Grade level 14.8 · Accepted 2025-09-12 16:30:09
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share TRML The Nasdaq Global Se
Filing Documents
- d40365d8k.htm (8-K) — 26KB
- 0001193125-25-202252.txt ( ) — 142KB
- trml-20250908.xsd (EX-101.SCH) — 3KB
- trml-20250908_lab.xml (EX-101.LAB) — 18KB
- trml-20250908_pre.xml (EX-101.PRE) — 11KB
- d40365d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Tourmaline Bio, Inc. Date: September 12, 2025 By: /s/ Ryan Robinson Ryan Robinson Chief Financial Officer 2